The duration of the conventional chemoembolization for hepatocellular carcinoma: factors affecting the procedural time

Abstract

Aim: The present study evaluated the duration of chemoembolization in patients with hepatocellular carcinoma, analyzing possible factors affecting the procedural time.

Methods: In total, 175 patients who underwent chemoembolization have been prospectively enrolled. The procedural length was considered the time between the insertion and the removal of the angiographic sheath. The features related to the tumor burden and angiographic procedures, which could be related to the procedural time, were recorded.

Results: The chemoembolization time resulted in a mean of 58.1 min. The longer procedural time was associated with a number of nodules treated per patient ≥ 2 (P < 0.001), a number of segments with nodules ≥ 2 (P < 0.001), the presence of more than 1 nodule in the same segment (P < 0.001), the location of the tumor in the left lobe (P = 0.001), the exclusion from the Milan criteria (P < 0.001), and a number of segments treated ≥ 2 (P < 0.001). Only the number of nodules treated per patient resulted significantly in multivariate analysis (OR 2.927, 95%CI: 2.015-4.251, P < 0.001).

Conclusion: The factors related to longer procedural time are the number of nodules treated ≥ 2, the number of segments with nodules ≥ 2, the involvement of the left lobe, the tumor burden outside the Milan criteria, and the number of segments treated ≥ 2. All these characteristics, known in the pre-procedural phase, represent useful tools for a correct planning of the angiographic room’s workflow during the pandemic era as well as in the future to reduce downtime and increase productivity.

Keywords

Chemoembolization / hepatocellular carcinoma / procedural time / angiographic room / management

References

[1] Chidambaranathan-reghupaty S,Sarkar D.Hepatocellular carcinoma (HCC): epidemiology, etiology and molecular classification.Adv Cancer Res2021;149:1-61 PMCID:PMC8796122

[2] Cucchetti A,Cescon M.Italian Liver Cancer (ITALI.CA) Group. Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population.J Hepatol2012;56:1089-96

[3] Renzulli M.Bologna Liver Oncology Group (BLOG)Proposal of a new diagnostic algorithm for hepatocellular carcinoma based on the Japanese guidelines but adapted to the Western world for patients under surveillance for chronic liver disease.J Gastroenterol Hepatol2016;31:69-80

[4] Liver cancer [homepage on the Internet]. The global cancer observatory cancer fact sheets (2018). Available from: http://gco.iarc.fr/today/data/factsheets/cancers/11-Liver-fact-sheet.pdf [Last accessed on 11 May 2022]

[5] Llovet JM.Hepatocellular carcinoma: present status and future prospects.J Hepatol2003;38:136-49

[6] Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma.J Hepatol2018;69:182-236

[7] Forner A,Varela M.Transarterial chemoembolization for patients with hepatocellular carcinoma.Hepatol Res2007;37 Suppl 2:S230-7

[8] Okuda K,Kimura K.Incidence of portal vein thrombosis in liver cirrhosis.Gastroenterology1985;89:279-86

[9] Facciorusso A,Muscatiello N,Barone M.Transarterial chemoembolization: evidences from the literature and applications in hepatocellular carcinoma patients.World J Hepatol2015;7:2009-19 PMCID:PMC4528274

[10] Tovoli F,Negrini G.Inter-operator variability and source of errors in tumour response assessment for hepatocellular carcinoma treated with sorafenib.Eur Radiol2018;28:3611-20

[11] Tovoli F,Casadei-Gardini A.Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients.J Hepatol2019;71:1175-83

[12] Zaky S,Abdel Malek MO.Multidisciplinary decision making in the management of hepatocellular carcinoma: a hospital-based study.Turk J Gastroenterol2015;26:498-505

[13] Varela M,de la Mata M.Treatment approach of hepatocellular carcinoma in Spain. Analysis of 705 patients from 62 centers.Med Clin (Barc)2010;134:569-76

[14] Giannini EG,Pellegatta G.Italian Liver Cancer (ITALI.CA) Group., Italian Liver Cancer ITA LI CA Group. Application of the intermediate-stage subclassification to patients with untreated hepatocellular carcinoma.Am J Gastroenterol2016;111:70-7

[15] Raoul JL,Bolondi L,Kloeckner R.Updated use of TACE for hepatocellular carcinoma treatment: how and when to use it based on clinical evidence.Cancer Treat Rev2019;72:28-36

[16] Maas M,Gaubert JY.Follow-up after radiological intervention in oncology: ECIO-ESOI evidence and consensus-based recommendations for clinical practice.Insights Imaging2020;11:83 PMCID:PMC7366866

[17] Karaosmanoglu AD,Uysal A,Ozmen MN.Tumor in the veins: an abdominal perspective with an emphasis on CT and MR imaging.Insights Imaging2020;11:52 PMCID:PMC7096619

[18] Vasuri F,Fiorentino M.OATP 1B1/1B3 expression in hepatocellular carcinomas treated with orthotopic liver transplantation.Virchows Arch2011;459:141-6

[19] Renzulli M,Argalia G.Morphological, dynamic and functional characteristics of liver pseudolesions and benign lesions.Radiol Med2022;127:129-44

[20] Renzulli M,Vasuri F.Standardization of conventional chemoembolization for hepatocellular carcinoma.Ann Hepatol2021;22:100278

[21] Idilman I,Cil BE.Transarterial chemoembolization for treatment of hepatocellular carcinoma: a single center experience.Turk J Gastroenterol2013;24:141-7

[22] Terzi E,Venerandi L.The ART score is not effective to select patients for transarterial chemoembolization retreatment in an Italian series.Dig Dis2014;32:711-6

[23] Cucchetti A,Cappelli A.Cost-effectiveness of doxorubicin-eluting beads versus conventional trans-arterial chemo-embolization for hepatocellular carcinoma.Dig Liver Dis2016;48:798-805

[24] Wu X,Malhotra A.Comparison of drug-eluting embolics versus conventional transarterial chemoembolization for the treatment of patients with unresectable hepatocellular carcinoma: a cost-effectiveness analysis.J Vasc Interv Radiol2021;32:2-12.e1

[25] Kudo M,Ye SL.A changing paradigm for the treatment of intermediate-stage hepatocellular carcinoma: asia-pacific primary liver cancer expert consensus statements.Liver Cancer2020;9:245-60 PMCID:PMC7325125

[26] Cavallo JJ.The economic impact of the COVID-19 pandemic on radiology practices.Radiology2020;296:E141-4 PMCID:PMC7233391

[27] Marasco G,Maida M,Pastorelli L.Italian Association of Young Gastroenterologist and Endoscopist (AGGEI)Impact of COVID-19 outbreak on clinical practice and training of young gastroenterologists: a European survey.Dig Liver Dis2020;52:1396-402 PMCID:PMC7245276

[28] Pramesh CS.Cancer management in India during Covid-19.N Engl J Med2020;382:e61 PMCID:PMC7207224

[29] Iacobucci G.How is the pandemic affecting non-covid services?.BMJ2021;372:n215

[30] Procopet B.Diagnosis of cirrhosis and portal hypertension: imaging, non-invasive markers of fibrosis and liver biopsy.Gastroenterol Rep (Oxf)2017;5:79-89 PMCID:PMC5421457

[31] Renzulli M,Ierardi AM.Validation of a standardized CT protocol for the evaluation of varices and porto-systemic shunts in cirrhotic patients.Eur J Radiol2022;147:110010

[32] Mosconi C,Biselli M.Survival and tolerability of transarterial chemoembolization in greater versus less than 70 Years of age patients with unresectable hepatocellular carcinoma: a propensity score analysis.Cardiovasc Intervent Radiol2020;43:1015-24

[33] Iwazawa J,Hashimoto N.Comparison of the number of image acquisitions and procedural time required for transarterial chemoembolization of hepatocellular carcinoma with and without tumor-feeder detection software.Radiol Res Pract2013;2013:580839 PMCID:PMC3745970

[34] Granito A,Sacco R.TRANS-TACE: prognostic role of the transient hypertransaminasemia after conventional chemoembolization for hepatocellular carcinoma.J Pers Med2021;11:1041 PMCID:PMC8539564

[35] Gui CH,D'cruz RT.Trans-arterial chemoembolization + radiofrequency ablation versus surgical resection in hepatocellular carcinoma - a meta-analysis.Eur J Surg Oncol2020;46:763-71

[36] Vogl TJ,Oppermann E.Early dynamic changes in circulating tumor cells and prognostic relevance following interventional radiological treatments in patients with hepatocellular carcinoma.PLoS One2021;16:e0246527 PMCID:PMC7880472

[37] Chen S,Zhang Y.Lack of response to transarterial chemoembolization for intermediate-stage hepatocellular carcinoma: abandon or repeat?.Radiology2021;298:680-92

[38] Campos JT,Choi JY.Focal hepatic lesions in Gd-EOB-DTPA enhanced MRI: the atlas.Insights Imaging2012;3:451-74 PMCID:PMC3443279

[39] Golfieri R,Ascanio S.Focal lesions in the cirrhotic liver: their pivotal role in gadoxetic acid-enhanced MRI and recognition by the Western guidelines.Dig Dis2014;32:696-704

[40] Park HJ,Kim SY.Non-enhanced magnetic resonance imaging as a surveillance tool for hepatocellular carcinoma: comparison with ultrasound.J Hepatol2020;72:718-24

[41] Compagnone G,Domenichelli S,Golfieri R.Calculation of conversion factors for effective dose for various interventional radiology procedures.Med Phys2012;39:2491-8